Adding abemaciclib to adjuvant endocrine therapy significantly reduces the risk for recurrence in patients with high-risk, hormone receptor-positive, HER2-negative, early breast cancer, show phase 3 trial findings.
The final overall survival results of the IMpassion130 trial continue to support the first-line use of atezolizumab plus nab-paclitaxel in PD-L1-expressing patients with metastatic triple-negative breast cancer.
Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.
Long-term ipsilateral breast tumor recurrence rates are similar whether women are treated with accelerated partial-breast irradiation or whole-breast irradiation, results of the phase 3 APBI-IMRT-Florence trial show.
In patients with early-stage breast cancer, shorter durations of adjuvant trastuzumab therapy are noninferior to the standard 1-year schedule with regard to disease-free survival, suggests an individual patient data meta-analysis.
Combining the PARP inhibitor veliparib with carboplatin and paclitaxel delays disease progression and death in patients with BRCA-mutated, HER2-negative advanced breast cancer, show data from the BROCADE3 trial.
Phase 3 results from China suggest that paclitaxel plus carboplatin could be an adjuvant therapy option for patients with operable triple-negative breast cancer.
Extending mammography screening to include women in their 40s may reduce breast cancer mortality rates compared with a later screening induction without increasing the risk for overdiagnosis, the UK Age trial investigators report.
The 5-year results of the TARGIT-A trial have demonstrated the noninferiority of risk-adapted, single-dose targeted intraoperative radiotherapy delivered during lumpectomy to conventional radiotherapy for the adjuvant treatment of early-stage breast cancer.
A post-hoc analysis of the BIG 1–98 trial has identified genetic variants associated with the risk for recurrence after 5 years of adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive, HER2-negative, early-stage breast cancer.
Supplementing capecitabine with neratinib instead of lapatinib is associated with a significant improvement in the progression-free survival of previously treated patients with metastatic HER2-positive breast cancer, shows the phase 3 NALA trial.
Two modelling studies published in The Lancet Oncology show the impact cancer diagnostic delays due to COVID-19 could have in England, with some scenarios suggesting over a 1000 people could die unnecessarily.
A database analysis indicates that adjuvant chemotherapy may prolong overall survival in patients aged at least 70 years with node- and estrogen receptor-positive breast cancer and multiple comorbidities.
The presence of circulating tumor DNA and circulating tumor cells in postsurgical samples is associated with relapse and poor outcomes in early-stage triple-negative breast cancer patients with an incomplete pathologic response to neoadjuvant chemotherapy, research suggests.
Women with early-stage breast cancer have a differential response to adjuvant docetaxel therapy according to their BMI, finds a post-hoc analysis of a phase 3 trial.
UK researchers have called for urgent action to be taken to avoid unnecessary cancer deaths as a result of delayed surgery due to the COVID-19 pandemic.